Our approach to immunotherapy is based on the streamlined combination of our Kiromic Artificial Intelligence (K.A.I) and Biomarker Lead Antigen Discovery Engine (BLADE) dual core technology for disease target identification and validation. K.A.I-BLADE is used in the development of therapies, serological tests and diagnostic tests. K.A.I-BLADE led to the development of our lead products BSK01 and BSK02.

Copyright © 2018 Kiromic. All rights reserved.